Tech Company Financing Transactions
Neos Therapeutics Funding Round
Neos Therapeutics closed a $15.5 million investment round on 3/4/2014. Investors included Burrill & Company, Crabtree Ventures and Delaware Street Capital.
Transaction Overview
Company Name
Announced On
3/4/2014
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$15,500,000
Round
Undisclosed
Proceeds Purpose
The funds will support the Company's efforts to obtain FDA approval of its existing product pipeline, and create an opportunity to expand the use of the proprietary controlled release technologies to develop additional CR orally disintegrating tablet and CR liquid products.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2940 N Hwy. 360 400
Grand Prairie, TX 75050
USA
Grand Prairie, TX 75050
USA
Phone
Website
Email Address
Overview
Neos Therapeutics (NASDAQ: NEOS) is a specialty pharmaceutical company that focuses on time-release technologies. We have developed a broad, cutting-edge portfolio of processes that allow for tailored and independent release profiles of single and multiple ingredients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jerry McLaughlin
Chief Financial Officer
Richard Eisenstadt
VP - General Counsel
John Limongelli
VP - Human Resources
Sarah Foster
VP - Operations
Margaret Cabano
VP - R & D
Russ McMahen
Browse more venture capital transactions:
Prev: 3/4/2014: Adapx venture capital transaction
Next: 3/4/2014: DocuSign venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs